search
Back to results

Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases

Primary Purpose

Small Bowel Disease

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
NaviCam SB
PillCam SB3
Sponsored by
Wuhan Union Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Small Bowel Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding;
  2. Those need capsule endoscopy because the recurring GI symptoms cannot be explained by other imaging methods;
  3. Those can understand and accept this study protocol and voluntarily sign an informed consent.

Exclusion Criteria:

  1. Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule;
  2. Patient with known gastrointestinal motility disorders;
  3. Patient with known or suspected gastrointestinal obstruction, stenosis or fistula;
  4. Patient with known or suspected delayed gastric emptying;
  5. Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions;
  6. Patient has any allergy or other known contraindication or intolerance to the medications used in the study;
  7. Patient has any condition, which precludes compliance with study and/or device instructions;
  8. Women who are either pregnant or nursing at the time of screening;
  9. Concurrent participation in another clinical trial using any investigational drug or device;
  10. Patient suffers from a life-threatening condition;
  11. Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters;
  12. Patients with pace-maker or implantable cardioverter other implantable electronic medical device;
  13. Patient with an easily magnetized metal part;
  14. Patient requires endoscopic placement of the capsule;
  15. Others considered by the investigator not suitable for this study.

Sites / Locations

  • Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

NaviCam SB

PillCam SB3

Arm Description

After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.

After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.

Outcomes

Primary Outcome Measures

Diagnostic agreement rate
The diagnosis of subjects by the two types of small bowel capsule endoscopes through independent image reading, that is, the agreement between the two systems with respect to the diagnosis of normal or abnormal subject.

Secondary Outcome Measures

Intestinal transit time
The time from capsule swallowing to capsule excretion
Ease of swallowing the capsule
The subject's supervisor determines how easy it is to swallow the capsule and which of the following feelings is very easy, easy, moderate, difficult, or very difficult.
diagnosis rate
Comparison of the diagnosis rate (examination results within one week before or after enrollment) with other standard mucosal imaging tools (upper GI endoscopy, enteroscopy, colonoscopy, etc.)
Quality of small bowel images
Comparison of the quality of small intestine pictures taken with the two capsules
Image reading time
Comparison of the reading times of the two capsules

Full Information

First Posted
September 30, 2021
Last Updated
September 14, 2023
Sponsor
Wuhan Union Hospital, China
Collaborators
Changhai Hospital, Qilu Hospital of Shandong University
search

1. Study Identification

Unique Protocol Identification Number
NCT05086471
Brief Title
Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases
Official Title
Performance Evaluation of the NaviCam SB Capsule Endoscope System in Comparison to the PillCam SB3 Capsule System for the Diagnosis of Small Bowel Diseases
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
September 23, 2021 (Actual)
Primary Completion Date
December 1, 2021 (Actual)
Study Completion Date
December 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wuhan Union Hospital, China
Collaborators
Changhai Hospital, Qilu Hospital of Shandong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study uses a comparative method to evaluate the performance of the NaviCam SB capsule endoscope system in comparison to the PillCam SB3 capsule system for the diagnosis of small bowel diseases.
Detailed Description
This study adopts a prospective and self-controlled design. The subjects are adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding; Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time. This study adopts a method of independent image reading in the participating centers. Two physicians of digestive endoscopy respectively review the images captured by the experimental capsule and the control capsule for normal versus abnormal findings, type of findings and categorization (lesions, polyps, bleeding, etc.), capsule transit time, reading time, and image quality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Small Bowel Disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
NaviCam SB
Arm Type
Experimental
Arm Description
After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
Arm Title
PillCam SB3
Arm Type
Other
Arm Description
After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
Intervention Type
Device
Intervention Name(s)
NaviCam SB
Intervention Description
Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
Intervention Type
Device
Intervention Name(s)
PillCam SB3
Intervention Description
Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time.
Primary Outcome Measure Information:
Title
Diagnostic agreement rate
Description
The diagnosis of subjects by the two types of small bowel capsule endoscopes through independent image reading, that is, the agreement between the two systems with respect to the diagnosis of normal or abnormal subject.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Intestinal transit time
Description
The time from capsule swallowing to capsule excretion
Time Frame
14 days
Title
Ease of swallowing the capsule
Description
The subject's supervisor determines how easy it is to swallow the capsule and which of the following feelings is very easy, easy, moderate, difficult, or very difficult.
Time Frame
14 days
Title
diagnosis rate
Description
Comparison of the diagnosis rate (examination results within one week before or after enrollment) with other standard mucosal imaging tools (upper GI endoscopy, enteroscopy, colonoscopy, etc.)
Time Frame
14 days
Title
Quality of small bowel images
Description
Comparison of the quality of small intestine pictures taken with the two capsules
Time Frame
14 days
Title
Image reading time
Description
Comparison of the reading times of the two capsules
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding; Those need capsule endoscopy because the recurring GI symptoms cannot be explained by other imaging methods; Those can understand and accept this study protocol and voluntarily sign an informed consent. Exclusion Criteria: Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule; Patient with known gastrointestinal motility disorders; Patient with known or suspected gastrointestinal obstruction, stenosis or fistula; Patient with known or suspected delayed gastric emptying; Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions; Patient has any allergy or other known contraindication or intolerance to the medications used in the study; Patient has any condition, which precludes compliance with study and/or device instructions; Women who are either pregnant or nursing at the time of screening; Concurrent participation in another clinical trial using any investigational drug or device; Patient suffers from a life-threatening condition; Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters; Patients with pace-maker or implantable cardioverter other implantable electronic medical device; Patient with an easily magnetized metal part; Patient requires endoscopic placement of the capsule; Others considered by the investigator not suitable for this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
XiaoHua Hou, MD.PhD
Organizational Affiliation
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rong Lin, MD.PhD
Organizational Affiliation
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases

We'll reach out to this number within 24 hrs